Fogarty International Center; Notice of Meeting, 27839-27840 [E8-10550]
Download as PDF
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 73, No. 94 / Wednesday, May 14, 2008 / Notices
phase of the regulatory review period,
while 183 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355(i)) became effective: January 24,
2000. The applicant claims October 2,
1999, as the date the investigational new
drug application (IND) became effective.
However, FDA records indicate that the
IND effective date was January 24, 2000,
which was the date the IND was
removed from clinical hold.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the act: April 7, 2006. The
applicant claims December 6, 2005, as
the date the new drug application
(NDA) for ZOLINZA (NDA 21–991) was
initially submitted. However, FDA
records indicate that NDA 21–991 was
submitted in several modules under the
fast track drug development program. It
is FDA’s position that the approval
phase begins when the marketing
application is complete for review. The
final module of the NDA making it
complete for review was submitted on
April 7, 2006.
3. The date the application was
approved: October 6, 2006. FDA has
verified the applicant’s claim that NDA
21–991 was approved on October 6,
2006.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the U.S. Patent and
Trademark Office applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 1,433 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments and ask for a
redetermination by July 14, 2008.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
November 10, 2008. To meet its burden,
the petition must contain sufficient facts
to merit an FDA investigation. (See H.
Rept. 857, part 1, 98th Cong., 2d sess.,
pp. 41–42, 1984.) Petitions should be in
the format specified in 21 CFR 10.30.
Comments and petitions should be
submitted to the Division of Dockets
Management. Three copies of any
mailed information are to be submitted,
except that individuals may submit one
VerDate Aug<31>2005
16:39 May 13, 2008
Jkt 214001
copy. Comments are to be identified
with the docket number found in
brackets in the heading of this
document. Comments and petitions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Please note that on January 15, 2008,
the FDA Division of Dockets
Management Web site transitioned to
the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. Electronic
comments or submissions will be
accepted by FDA through FDMS only.
Dated: April 28, 2008.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. E8–10689 Filed 5–13–08; 8:45 am]
27839
grantees with expiring or recently
expired project periods.’’
FOR FURTHER INFORMATION CONTACT:
Maribeth Badura, Director, Division of
Healthy Start and Perinatal Services,
Maternal and Child Health Bureau,
HRSA, Room 18–12, Parklawn Building,
5600 Fishers Lane, Rockville, Maryland
20857; telephone (301) 443–0543; e-mail
MBadura@hrsa.gov.
Dated: May 2, 2008.
Dennis Williams,
Acting Administrator.
[FR Doc. E8–10684 Filed 5–13–08; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4160–01–S
Fogarty International Center; Notice of
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Preference for Healthy Start Grantees
Health Resources and Services
Administration (HRSA), HHS.
ACTION: General notice.
AGENCY:
This notice supplements
the 2007 HRSA announcement (HRSA
08–023/08–031) of the availability of
fiscal year (FY) 2008 funding for new
and competing continuation
applications for Healthy Start. Healthy
Start strengthens communities to
effectively address the causes of infant
mortality, low birth weight and other
poor perinatal outcomes for women and
infants. Recently, new guidance became
available with regards to funding FY
2008 Healthy Start programs.
SUMMARY: The Conference Report (H.R.
Rep. No. 110–107) accompanying the
Consolidated Appropriations Act 2008
(Pub. L. 110–161), Division G—
Departments of Labor, Health and
Human Services, and Education, and
Related Agencies Appropriations Act,
2008, indicates concurrence with the
Senate report language regarding the
recompetition of Healthy Start
programs. Following the Senate
Committee’s recommendation, the
Health Resources and Services
Administration (HRSA) will give
funding preference during the FY 2008
competition to current Healthy Start
grantees.
Senate Report 110–107 urges ‘‘HRSA
to give preference to current and former
BACKGROUND:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Fogarty International Center Advisory
Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(9)(B), Title 5 U.S.C., as
amended. The grant applications and/or
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications
and/or contract proposals, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: Fogarty International
Center Advisory Board.
Date: May 19–20, 2008.
Closed: May 19, 2008, 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Closed: May 20, 2008, 8:30 a.m. to 10:30
a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
E:\FR\FM\14MYN1.SGM
14MYN1
27840
Federal Register / Vol. 73, No. 94 / Wednesday, May 14, 2008 / Notices
jlentini on PROD1PC65 with NOTICES
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Open: May 20, 2008, 10:30 a.m.to 12:30
p.m.
Agenda: A report of the FIC Director on
updates and overviews of new FIC initiatives.
Topics to be discussed include the Global
Programs and Strategies of the NCI and
NHLBI.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Closed: May 20, 2008, 1:30 p.m. to 3:15
p.m.
Agenda: To review and evaluate a report
and discussion on the Global Health Leaders
Consultation.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Contact Person: Robert Eiss, Public Health
Advisor, Fogarty International Center,
National Institutes of Health, 31 Center Drive,
Room B2C02, Bethesda, MD 20892, (301)
496–1415, eissr@mail.nih.gov.
This meeting is being published less than
15 days prior to the meeting due to timing
limitations imposed by administrative
matters.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Centers home page: https://
www.nih.gov/fic/about, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.106, Minority International
Research Training Grant in the Biomedical
and Behavioral Sciences; 93.154, Special
International Postdoctoral Research Program
in Acquired Immunodeficiency Syndrome;
93.168, International Cooperative
Biodiversity Groups Program; 93.934, Fogarty
International Research Collaboration Award;
93.989, Senior International Fellowship
Awards Program, National Institutes of
Health, HHS)
Dated: May 6, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–10550 Filed 5–13–08; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005
16:39 May 13, 2008
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Child Health and
Human Development Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Child Health and Human Development
Council.
Date: June 12, 2008.
Open: 8 a.m. to 1:30 p.m.
Agenda: (1) A report by the Director,
NICHD; (2) A report of the Subcommittee on
Planning and Policy; (3) A Contraception and
Reproductive Health Branch Presentation;
and other business of the Council.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C-Wing,
Conference Room 6, Bethesda, MD 20892.
Closed: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C-Wing,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Yvonne T. Maddox, PhD,
Deputy Director, National Institute of Child
Health and Human Development, NIH, 9000
Rockville Pike, MSC 7510, Building 31,
Room 2A03, Bethesda, MD 20892, (301) 496–
1848.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuffles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/nachhd.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: May 5, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–10469 Filed 5–13–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources, Special Emphasis Panel
R24 Applications Review.
Date: June 17, 2008.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health/NCRR/
OR, Democracy 1, 6701 Democracy Blvd.,
Room 1064, Bethesda, MD. (Telephone
Conference Call).
Contact Person: Guo Zhang, PhD.,
Scientific Review Officer, Office of Review,
National Center for Research Resources,
National Institutes of Health, 6701
Democracy Boulevard, 1 Democracy Plaza,
Room 1064, Bethesda, MD 20814–9692, (301)
435–0812, zhanggumail.nih.gov.
E:\FR\FM\14MYN1.SGM
14MYN1
Agencies
[Federal Register Volume 73, Number 94 (Wednesday, May 14, 2008)]
[Notices]
[Pages 27839-27840]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-10550]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the Fogarty International Center Advisory Board.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as
amended. The grant applications and/or contract proposals and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications and/or
contract proposals, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Fogarty International Center Advisory Board.
Date: May 19-20, 2008.
Closed: May 19, 2008, 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Lawton Chiles
International House, Bethesda, MD 20892.
Closed: May 20, 2008, 8:30 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant applications and/or
proposals.
[[Page 27840]]
Place: National Institutes of Health, Lawton Chiles
International House, Bethesda, MD 20892.
Open: May 20, 2008, 10:30 a.m.to 12:30 p.m.
Agenda: A report of the FIC Director on updates and overviews of
new FIC initiatives. Topics to be discussed include the Global
Programs and Strategies of the NCI and NHLBI.
Place: National Institutes of Health, Lawton Chiles
International House, Bethesda, MD 20892.
Closed: May 20, 2008, 1:30 p.m. to 3:15 p.m.
Agenda: To review and evaluate a report and discussion on the
Global Health Leaders Consultation.
Place: National Institutes of Health, Lawton Chiles
International House, Bethesda, MD 20892.
Contact Person: Robert Eiss, Public Health Advisor, Fogarty
International Center, National Institutes of Health, 31 Center
Drive, Room B2C02, Bethesda, MD 20892, (301) 496-1415,
eissr@mail.nih.gov.
This meeting is being published less than 15 days prior to the
meeting due to timing limitations imposed by administrative matters.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Centers home
page: https://www.nih.gov/fic/about, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.106,
Minority International Research Training Grant in the Biomedical and
Behavioral Sciences; 93.154, Special International Postdoctoral
Research Program in Acquired Immunodeficiency Syndrome; 93.168,
International Cooperative Biodiversity Groups Program; 93.934,
Fogarty International Research Collaboration Award; 93.989, Senior
International Fellowship Awards Program, National Institutes of
Health, HHS)
Dated: May 6, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-10550 Filed 5-13-08; 8:45 am]
BILLING CODE 4140-01-M